PDCD1 and neoplasm: Inhibitors of CDK4, GSK3B, and PTK2 could enhance tumour response to anti-PD-1 immunotherapy.248 Likewise, increased Ki-67+PD-1+CD8 T cells can be detected in blood samples of NSCLC patients and related to PD-1 targeted therapy responses.